Monitor for next clinical milestones such as IND filing or Phase 1 initiation. The preclinical data supports the platform but is early-stage; stock movement likely limited until human data is available.
Price Chart
Executive Summary
OPKO Health presented preclinical data for OPK8801001, a long-acting hGH receptor antagonist for acromegaly, at ENDO 2026. In vitro data showed 20-fold greater potency than Pegvisomant, and in vivo data demonstrated dose-dependent IGF-1 suppression, suggesting potential for weekly dosing. However, these are early preclinical results with no clinical or regulatory milestones, limiting near-term impact.
Key Facts
- OPK8801001 is a novel long-acting hGH receptor antagonist for acromegaly.
- In vitro data showed approximately 20-fold greater potency than Pegvisomant.
- In vivo data demonstrated robust, dose-dependent, sustained suppression of IGF-1.
- Preclinical findings suggest potential for a once-weekly treatment alternative to daily therapies.
- Data presented at ENDO 2026, the Endocrine Society's annual meeting.
Financial Impact
No financial data provided; preclinical stage with no revenue impact.
Risk Factors
- Preclinical results may not translate to clinical efficacy or safety.
- Competition from existing acromegaly therapies (e.g., Pegvisomant, somatostatin analogs).
- Regulatory and development risks for a novel biologic candidate.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311726 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 27, 2026 9w ago | 8-K | $1.65 $1.49 | ▼ −9.70% | ▼ −13.08% | $1.56 (−5.45%) |
Jul 23, 2026 10w ago | Press Release | $1.17 $1.46 | ▲ +24.79% | ▲ +21.48% | $1.56 (+33.33%) |
Jun 15, 2026 15w ago | Press Release | $1.40 $1.23 | ▼ −12.14% | ▼ −11.39% | $1.56 (+11.43%) |
May 15, 2026 20w ago | DEFA14A | $1.13 $1.39 | ▲ +23.01% | ▲ +21.43% | $1.56 (+38.05%) |
Apr 30, 2026 22w ago | Press Release | $1.13 $1.43 | ▲ +26.55% | ▲ +21.58% | $1.56 (+38.05%) |
Apr 22, 2026 23w ago | Press Release | $1.23 $1.15 | ▼ −6.50% | ▼ −9.67% | $1.56 (+26.83%) |
Apr 21, 2026 23w ago | Press Release | $1.23 $1.15 | ▼ −6.50% | ▼ −9.67% | $1.56 (+26.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access